Trials / Unknown
UnknownNCT02363361
Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study
Treatment of Acute Cervical Spinal Cord Injury With Imatinib (Glivec®) - a Safety and Feasibility Study (EudraCT no 2014-002170-36)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Professor Mikael Svensson, MD PhD · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II, single center, open-label, non randomized clinical study to assess the uptake, safety and tolerability of Imatinib in acute Cervical Spinal Cord Injury patients. The aim is to determine if Imatinib reaches sufficient blood levels when given to patients with cervical spinal cord injury, via a gastric feeding tube, and also evaluate the safety and tolerability of this drug treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
- First posted
- 2015-02-16
- Last updated
- 2018-03-07
Source: ClinicalTrials.gov record NCT02363361. Inclusion in this directory is not an endorsement.